Efficacy of pregabalin as a monotherapy versus combined pregabalin and milnacipran in the management of fibromyalgia.
Leeds Sleep Evaluation Questionnaire
fibromyalgia
fibromyalgia impact questionnaire
milancipran
pregabalin
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
30
05
2020
revised:
06
07
2020
accepted:
03
08
2020
pubmed:
5
9
2020
medline:
16
9
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
To compare the efficacy and tolerability of combined pregabalin (PGB) and milnacipran (MLN) in female patients with fibromyalgia (FM) versus PGB as a monotherapy. The present randomized open study included 58 female patients diagnosed with FM (registered on 4/2/19: NCT03905486). Patients were randomly divided into 2 groups (2:2); group 1 included 29 patients who received PGB monotherapy (150 mg twice daily) and group 2 included 29 patients who received combined PGB (150 mg twice daily) and MLN (50 mg twice daily) for 3 months. At the initial visit, patients were subjected to demographic data collection and assessed by the visual analog scale (VAS) for pain and the FM impact questionnaire (FIQ). Outcome measures after 3 months: FIQ, VAS and Leeds Sleep Evaluation Questionnaire. The median disease duration was 2 years in group 1 (6 months to 5 years) and 2 years in group 2 (6 months to 12 years). The dropout rate was 20.7% in group 1 (n = 6) and 10.3% in group 2 (n = 3). At the follow-up evaluation, a statistically significant improvement was observed in VAS and FIQ scores in both groups (P < 0.001). Although the percentage of patients demonstrating significant improvement in pain, disease impact and sleep pattern were higher in group 2, this did not reach statistical significance. Although PGB as a monotherapy and in combination with MLN have both shown adequate efficacy in the treatment of patients with FM, the combined therapy did not demonstrate superiority over the monotherapy.
Identifiants
pubmed: 32886447
doi: 10.1111/1756-185X.13953
doi:
Substances chimiques
Analgesics, Non-Narcotic
0
Pregabalin
55JG375S6M
Milnacipran
G56VK1HF36
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1474-1480Informations de copyright
© 2020 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Borchers AT, Gershwin ME. Fibromyalgia: a critical and comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):100-151.
Macfarlane G, Kronisch C, Dean L, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328.
Marques AP, do de Espírito Santo AS, Berssaneti AA, Matsutani LAYuan SLK Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017;57(4):356-363.
Kaltsas G, Fibromyalgia TK.Endotext [Internet]: MDText. com, Inc.; 2020. www.endotext.org
FDA US.Living with fibromyalgia, drugs approved to manage pain Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107802.htm#approved. 2013 [updated January 31, 2014; Accessed: July 30, 216].
Alles SRA, Cain SM, Snutch TP. Pregabalin as a pain therapeutic: beyond calcium channels. Front Cell Neurosci. 2020;14:83.
Onuțu AH, Dîrzu DS, Petrișor C. Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management. In Ying Q (Eds.), Serotonin. Serotonin: IntechOpen; 2018. https://doi.org/10.5772/intechopen.80711
Choy EH. Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. Pain Manag. 2016;6(4):339-346.
Mease PJ, Farmer MV, Palmer RH, Gendreau RM, Trugman JM, Wang Y. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis. 2013;5(3):113-126.
Arnold LM. Advances in the management of fibromyalgia. CNS Spectr. 2009;14(S8):12-16.
Pfizer Inc., Lyrica (pregabalin), prescribing information. Available at: www.lyrica.com 2012 [accessed 14 January 2013]
Forest Laboratories Inc., Savella (milnacipran), prescribing information. Available at: http://www.savella.com. 2012 [accessed 14 January 2013].
Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Häuser F, Katz RL, et al. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. , et al. Semin Arthritis Rheum. 2016;46(3):319-329. https://doi.org/10.1016/j.semarthrit.2016.08.012
Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792-805.
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), mcgill pain questionnaire (MPQ), short-form mcgill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63(S11):S240-S252.
El-Naby MA, Hefny MA, Fahim AE, Awadalla MA. Validation of an adapted Arabic version of fibromyalgia syndrome impact questionnaire. Rheumatol Int. 2013;33(10):2561-2567.
Bennett R. The fibromyalgia impact questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(5):S154.
Parrott A, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations-a review. Psychopharmacology. 1980;71(2):173-179.
Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105-121.
Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36(6):1304-1311.
Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(5):663-672.
Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639-656.
Pae C-U, Marks DM, Shah M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009;32(6):355-363.
Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. DARU Journal of Pharmaceutical Sciences. 2019;27(1):149.
Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419-431.
Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2005;52(4):1264-1273.
Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002;17(Suppl 1):S25-S35.
Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505-521.
Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9:CD011790.
Arnold LM, Choy E, Clauw DJ, et al. An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr Med Res Opin. 2018;34(8):1397-1409.
Lawson K. Sleep dysfunction in fibromyalgia and therapeutic approach options. OBM Neurobiol. 2020;4(1):16.